Quantoom Biosciences
Univercells announced the acquisition of SynHelix in January 2022.
SynHelix is now part of Quantoom Biosciences, a Univercells company.
Visit Quantoom Biosciences



SynHelix arises from an incubation stage within the SHAKER program followed by the BOOSTER acceleration program launched by Genopole. At each step of our progress, the project has been evaluated by an independent expert committee for the innovativeness and the potential for future impact on biomedical research

About Genopole

Since May 2019, SynHelix is accompanied by the healthcare accelerator program of WILCO after being selected by a jury of experts (composed by entrepreneurs, business angels and scientists), obtaining one of the best evaluations of the batch.
The acceleration program includes :
- An honour loan financing tool for a total amount of 150k€
-A 3 years-acceleration program with individual support and collective workshop to secure the development strategy, the go-to-market and the commercial deployment of the solution